Research and Markets - Global Venous Thromboembolism Drug Forecast and Market Analysis to 2025 Featuring Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo & Portola

DUBLIN, Jan 20, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025" report to their offering.

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual's deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins of the lower extremities, it can embolize, potentially occluding blood vessels in the lungs.

Consequently, the vast majority of patients presenting with symptomatic pulmonary embolism also suffer from deep vein thrombosis, and many individuals diagnosed with deep vein thrombosis display pulmonary embolism that is asymptomatic. VTE can arise in both non-hospitalized and hospitalized individuals, repeatedly returns, and can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH).

Key Questions Answered

- The NOACs will see a significant increase in patient shares for the treatment of VTE and VTE primary prophylaxis against the established vitamin K antagonists and heparins. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the VTE market?
- The current late-stage VTE pipeline consists of betrixaban, in particular, which is vying for entry into the VTE market as the first NOAC approved for extended prophylaxis in acute medically ill patients- a significant unmet need in VTE space. Xarelto is also contending for entry in this space through an additional label expansion for the established therapy. Will the late-stage drugs make a significant impact on the VTE market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- We have seen a significant increase in the VTE population, in terms of diagnosed incidence and recurrent attacks, as well as an increase in the prophylaxis population. How will epidemiological changes impact the growth of the future market?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology
3.2 Symptoms
3.3 Prognosis
3.4 Quality of Life

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for VTE, 2015-2025
4.6 Discussion

5 Disease Management

5.1 Diagnosis and Treatment Overview

6 Competitive Assessment

6.1 Overview
6.2 Product Profiles - Oral Anticoagulants
6.2.1 Warfarin (Widely Genericized)
6.2.2 Pradaxa (dabigatran)
6.2.3 Xarelto (rivaroxaban)
6.2.4 Eliquis (apixaban)
6.2.5 Savaysa (edoxaban)
6.3 Product Profiles - Other Treatments
6.3.1 Heparins
6.3.2 Arixtra (fondaparinux)
6.3.3 Antiplatelets - Aspirin (Widely Genericized)

7 Unmet Needs and Opportunities

7.1 Overview
7.2 Unmet Needs and Opportunities
7.2.1 Inadequate Prophylaxis in Acute Medically Ill Patients
7.2.2 Complicated Dose Adjustments with New Oral Anticoagulants
7.2.3 Optimal Therapy for Cancer Patients
7.2.4 Optimal Therapy for Patients with Moderate and Severe Renal Failure
7.2.5 Physician Education on Clinical Benefits of New Oral Anticoagulants among Orthopedic Surgeons in the US
7.2.6 Reversal Agents for New Oral Anticoagulants
7.3 Opportunities for Drug Development in the VTE Market
7.3.1 Target Opportunity Profile - VTE Prophylaxis in Acute Medically Ill Patients
7.3.2 Target Opportunity Profile - VTE Patients with Cancer
7.3.3 Target Opportunity Profile - VTE Patients with Renal Impairment
7.3.4 Target Opportunity Profile - VTE Prophylaxis in THR and TKR Patients
7.3.5 Target Opportunity Profile - VTE Prophylaxis in Hip Fracture Surgery Patients

8 Pipeline Assessment

8.1 Overview
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Country
8.2.2 Clinical Trials by Phase and Trial Status
8.3 Promising Drugs in Clinical Development
8.3.1 Betrixaban (betrixaban)
8.3.2 Xarelto (rivaroxaban)
8.4 Other Drugs in Development
8.4.1 Early-Stage Anticoagulant Pipeline
8.4.2 Other Late-Stage Clinical Trials of the NOACs in VTE

9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles

10 Market Outlook

11 Appendix

Companies Mentioned

• Boehringer Ingelheim
• Bayer
• Janssen (Johnson & Johnson)
• Bristol-Myers Squibb
• Pfizer
• Daiichi-Sankyo
• Portola Pharmaceuticals

For more information about this report visit http://www.researchandmarkets.com/research/fqk87n/pharmapoint

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]